Meet our
Scientific Advisory Board
Rhian M. Touyz, MBBCh, MSc (Med), PhD, FRCP, FRSE, FMedSci, FCAHS
Board Member
Dr. Touyz is the Executive Director and Chief Scientific Officer of the Research Institute of the McGill University Health Centre (RI-MUHC) and the Dr. Phil Gold Chair in Medicine, McGill University, Montreal, Canada. Until September 2021, she was the Director of the Institute of Cardiovascular & Medical Sciences (ICAMS) and British Heart Foundation (BHF) Chair and Professor of Cardiovascular Medicine, Univ of Glasgow. From 2005-2011 she held a Canada Research Chair in Hypertension (Tier 1). She is a clinician-scientist with an interest in molecular and vascular mechanisms of hypertension, and her research spans molecular to clinical studies.
Dr. Touyz graduated with her BSc (Hons) (1980), MBBCh (1984), MSc (1986) and PhD (1992) from the University of Witwatersrand, South Africa. She completed a post-doctoral fellowship at the IRCM, Montreal. She has received numerous awards, including: Dahl Award, Harriet Dustan Award, Hypertension Research Excellence Award (Council on hypertension, AHA), Robert M. Berne Award (American Physiological Society), RD Wright Award (BPRC, Australia), Irvine Page Award (ASH), Joan Mott Award (Physiology Society). She is the incoming editor-in-chief of Hypertension.
She contributes to best clinical practice and co-chaired CHEP for clinical guidelines. She is a committee member for Guidelines of the European Society of Cardiology. She played major leadership roles in premier hypertension organisations: President-Canadian Hypertension Society, Chair-High BP Research Council (AHA), President-International Society of Hypertension and President-European Council for Cardiovascular Research. She has trained over 70 PhD/MD students and fellows and has published over 550 papers [h- index:121 (Google Scholar). Her research has been funded by the CIHR, HSFC, JDRF, BHF, MRC and Wellcome Trust.
Her research focuses on molecular and vascular biology of hypertension and target organ damage, particularly: 1) vascular signaling and redox biology; 2) vascular biology of cations and TRPM channels; 3) cardiovascular toxicity of anti-cancer drugs, 4) pathophysiology and management of human hypertension.
BackDr. Touyz graduated with her BSc (Hons) (1980), MBBCh (1984), MSc (1986) and PhD (1992) from the University of Witwatersrand, South Africa. She completed a post-doctoral fellowship at the IRCM, Montreal. She has received numerous awards, including: Dahl Award, Harriet Dustan Award, Hypertension Research Excellence Award (Council on hypertension, AHA), Robert M. Berne Award (American Physiological Society), RD Wright Award (BPRC, Australia), Irvine Page Award (ASH), Joan Mott Award (Physiology Society). She is the incoming editor-in-chief of Hypertension.
She contributes to best clinical practice and co-chaired CHEP for clinical guidelines. She is a committee member for Guidelines of the European Society of Cardiology. She played major leadership roles in premier hypertension organisations: President-Canadian Hypertension Society, Chair-High BP Research Council (AHA), President-International Society of Hypertension and President-European Council for Cardiovascular Research. She has trained over 70 PhD/MD students and fellows and has published over 550 papers [h- index:121 (Google Scholar). Her research has been funded by the CIHR, HSFC, JDRF, BHF, MRC and Wellcome Trust.
Her research focuses on molecular and vascular biology of hypertension and target organ damage, particularly: 1) vascular signaling and redox biology; 2) vascular biology of cations and TRPM channels; 3) cardiovascular toxicity of anti-cancer drugs, 4) pathophysiology and management of human hypertension.
Rosalind & Morris Goodman Cancer Institute all rights reserved • Privacy policy • Accessibility
Website by Riposte
